Physician profile
Timothy A Kisla
NPI 1477557445
$4,473.24
in general payments reported to CMS, 2019-2025
24 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $89.58 · 2021: $253 · 2022: $321 · 2023: $574 · 2024: $2,001 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507 · Education: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.92 |
| Education | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,678.73 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Alcon Vision LLC | $726.88 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $332.86 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $275.52 | 2019 | |
| Allergan, INC. | $192.50 | 2019-2022 | |
| Abbvie INC. | $186.09 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $135.67 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $101.59 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $100.20 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $97.02 | 2023-2025 | Dextenza |
| Oyster Point Pharma, INC. | $81.70 | 2022-2024 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec, INC. | $81.41 | 2019 | |
| Glaukos Corporation | $70.53 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $66.95 | 2022 | |
| Sight Sciences, INC. | $63.69 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $58.25 | 2019 | |
| Harrow Eye, LLC | $53.29 | 2024-2025 | Vevye, Iheezo |
| Novartis Pharmaceuticals Corporation | $33.31 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $30.75 | 2025 | |
| Eyevance Pharmaceuticals LLC | $29.22 | 2021 | |
| Dompe US, INC. | $26.14 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $18.75 | 2023 | |
| Optos, INC. | $16.90 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Kisla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.